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(continuously coded and that of all possible 
thresholds) with recurrence-free and 





Of 432 patients undergoing RNU with 
lymphadenectomy, 135 (31%) had LN 
metastases. Within a median follow-up of 
4.1 years, 90 of the 135 patients with LN 
metastases (68%) had disease recurrence 





) 5-year recurrence-free and DSS 
probabilities were 27 (4)% and 33 (5)%, 
respectively. The median (range) LND was 50 
(3–100)%. The most informative threshold 
for LND in relation to outcome was 30%. In 
multivariable analyses that adjusted for the 
effects of tumour stage and grade, patients 




30% were at greater risk of 
both cancer recurrence, with 5-year rates 








 0.021) and mortality, with 5-year rates of 








 0.032) compared 




30%. Our results are 
primarily limited by a lack of standardization 




We evaluated the concept of LND for the 
first time in UTUC. LND provides additional 
prognostic information in patients with 
node-positive disease after RNU. The use of 
LND in clinical trials might provide an 
additional insight into the value of LN 




urothelial carcinoma, urinary tract cancer, 
lymphatic metastases, lymph node 
dissection, prognosis 
Study Type – Prognosis (retrospective 
cohort study)




To determine the risk factors associated with 
clinical outcome in patients with lymph node 
(LN)-positive urothelial carcinoma of the 
upper urinary tract (UTUC) treated with 
radical nephroureterectomy (RNU) and 
lymphadenectomy, focusing on the concept 




Patients undergoing RNU with regional 
lymphadenectomy were identified through 
multi-institutional databases. All pathology 
slides were re-evaluated by genitourinary 
pathologists unaware of the clinical data. 




Radical nephroureterectomy (RNU) with 
removal of a bladder cuff is the standard 
and most effective treatment for patients 
with invasive upper tract urothelial 
carcinoma (UTUC) [1–3]. Of patients with 
UTUC, 20–40% have locally advanced disease 
with lymph node (LN) metastases at the time 
of diagnosis [4–6], with a 5-year disease-
specific survival (DSS) probability reported 
as low as 12% [7]. Both in LN-positive 
UTUC and bladder UC, adjuvant treatment 
strategies after surgery, e.g. chemotherapy or 
radiotherapy, have been used in an attempt to 
improve survival [8,9].
To date, there are no data on risk stratification 
of patients undergoing RNU with 
lymphadenectomy for LN-positive UTUC. 
Lymphadenectomy allows accurate tumour 
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staging and there is recent evidence of 
therapeutic effects in both patients with or 
with no LN metastases [4,10]. In bladder UC, 
radical cystectomy with lymphadenectomy 
alone might cure 5–34% of patients with 
microscopic LN-positive disease [11]. 
Extended lymphadenectomy also adds 
significant therapeutic benefit in both LN-
negative and -positive bladder UC [12–14]. 
For UTUC it was also recently reported that 
extended lymphadenectomy in addition to 
RNU provides a survival benefit in patients 
with locally advanced UTUC [4–6,15].
Despite the evidence of diagnostic and 
potential therapeutic benefits of LN 
dissection for UC, lymphadenectomy is 
used sporadically and haphazardly for UTUC. 
Absolute numbers of LNs and number of 
positive LNs reported in most series fail to 
capture the disease burden in the patient and 
the extent of dissection by the surgeon. LN 
density (LND) (the percentage of the number 
of LNs involved with tumour divided by the 
total number of LNs examined) has been 
evaluated in bladder UC [14]. Several studies 
suggest that the LND might have greater 
prognostic value than absolute numbers of 
involved LNs because it takes into account the 
potential therapeutic value of an extended 
LN dissection [14,16,17]. We evaluated the 
effect of LND on recurrence-free and DSS in 
a multi-institutional retrospective cohort 





Institutional review board approval was 
obtained by all 12 study sites in accordance 
with local regulations. A computerized 
databank was generated for data transfer (UT 
Southwestern Medical Center, Dallas, Texas). 
Data integrity was insured during integration 
and initial data analysis by resolving data 
inconsistency with the local study sites. 
Before the final analysis, the database was 
‘frozen’ from any additional modifications 
and the final dataset was produced for the 
current analysis.
Of 1363 patients who had RNU between 
1992 and 2006, 432 (31.7%) were identified 
who had a lymphadenectomy with removal of 
at least one LN involved with tumour in 
addition to RNU. The present study focuses on 
the 135 (31.3%) patients who had LN-positive 
disease.
Regional lymphadenectomy was generally 
performed in patients with enlarged LNs 
on preoperative axial imaging or with 
adenopathy detected during surgery. The 
lymphadenectomy template was not 
standardized. Of the 135 patients with LN-
positive disease, 119 (88.1%) had open and 16 
(11.9%) laparoscopic RNU. Although not 
standardized due to the multi-institutional 
nature of the study, lymphadenectomy 
comprised the para-aortic, paracaval or inter-
aortocaval nodes from the hilus to the inferior 
mesenteric artery for renal pelvic and 
proximally ureteric tumours, the renal hilus to 
the bifurcation of the common iliac artery for 
mid-ureteric tumours, and ipsilateral pelvic 
nodes for distal ureteric tumours. Overall, 
57 patients (43.2%) received adjuvant 
chemotherapy; none of the patients received 
neoadjuvant treatment.
The total number of identified LNs and the 
number of LNs involved with primary 
urothelial tumours were documented. All 
pathological slides were re-reviewed by 
genitourinary pathologists according to 
strictly defined criteria and blinded to the 
original pathology slides and clinical 
outcomes. The disease was staged 
pathologically according to the 2002 TNM 
classification of the American Joint 
Committee on Cancer. Tumours were graded 
according to the 1998 WHO/International 
Society of Urologic Pathology consensus 
classification [18]. Besides tumour staging 
and grading, the presence of significant 
tumour necrosis (threshold 10%), 





 (CIS) were 
assessed in every representative section.
Patients were generally followed every 3–4 
months for the first year, semi-annually 
from the second to the fifth, and annually 
thereafter. The follow-up comprised a 
physical examination, routine serum 
chemistry studies, radiographic evaluation 
of the contralateral remaining UT and the 
urinary bladder, and chest radiography. 
Elective bone scans and chest/abdominal/
pelvic CT or MRI were used when clinically 
indicated. The median (range) follow-up was 
4.1 (0.9–14.0) years.
The cause of death was determined by 
the treating physicians, by chart review 
corroborated by death certificates, or by death 
certificates alone. Perioperative mortality (any 
death within 30 days of surgery or before 
discharge) was censored at time of death for 
UC-specific survival analyses.
Univariable recurrence and survival 
probabilities after RNU were estimated using 
the Kaplan-Meier method. Univariable and 
multivariable Cox regression models 
addressed time to recurrence and disease-
specific mortality after RNU. In all models 
proportional hazards assumptions were 
systematically verified, using the Grambsch-
Therneau residual-based test [19]. The change 
in predictive accuracy resulting from adding 
variables of interest to standard predictor 
variables was quantified with Harrell’s 
concordance index [20,21]. A value of 1.0 
indicates perfect predictions, while 0.5 is 
equivalent to random chance. Internal 
validation was performed using 200-
bootstrap re-samples [20,21]. Estimates of 
predictive accuracy were expressed as 
proportions and compared using the Mantel-
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Table 1 summarizes the clinical and 
pathological characteristics of 135 patients 
with LN-positive UTUC. The proportion of 
patients with LVI among the LN-positive 
patients was significantly higher than in 
those with stage pN0 (297) in which 









 0.001). When considering the 
dominant urothelial lesion (as determined by 
pathological size and T classification), 73% of 
tumours were in the renal pelvis and 27% in 
the ureter.
In a preliminary study we assessed the 
discriminative value of each LND threshold for 
prognosis. Kaplan-Meier analyses of serial 
increments of the percentage threshold 
showed that a threshold of 30% was the best 
discriminator for both cancer recurrence and 
survival (data not shown). Overall, 96 patients 





Within a median follow-up of 4.1 years, 90 
patients (66.7%) had disease recurrence and 





and 10-year recurrence-free survival (RFS) 
probabilities were 27 (4)% and 26 (4)%, 
respectively; the 5- and 10-year DSS 
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probabilities were 33 (5)% and 32 (5)%, 
respectively. The median time to disease 
recurrence was 1 year and the median time 
to cancer-specific death 2.1 years. When 
compared with the 297 patients who had 
a lymphadenectomy and had pN0 disease, 
patients with LN-positive disease had a 


















 0.004) rates after adjusting for the 
effects of tumour stage, grade and LVI.
Table 2 shows the univariable and 
multivariable Cox regression analyses 
predicting disease recurrence and disease-
specific death. A higher pathological tumour 
stage of the primary UTUC was associated 


















 0.001). When analysed 
separately, neither the total number of LNs 
examined nor the total number of LNs 









 0.73 and 0.99, 








 0.66 and 0.43, 
respectively).




30% were at 
significantly greater risk of both disease 









 0.021) and mortality, with 5-year 













30% (Fig. 1). In 
multivariable analyses that adjusted for the 
effects of tumour stage, grade and LVI, LND 
coded as a continuous variables was not 
associated with cancer recurrence or DSS. 
However, using the threshold of 30%, LND 
was independently associated with both 








 0.005 and 
0.004, respectively).
The accuracies for predicting tumour 
recurrence and DSS of the base model 
comprising pT stage, tumour grade and LVI 
were 65.2% and 64.9%, respectively. Adding 
LND using the 30% threshold significantly 
improved the predictive accuracies for both 










Adjuvant chemotherapy (59 patients) was 


















 0.19). Adjuvant chemotherapy had no 

















 0.246). Analyses were re-run after 
stratifying by adjuvant therapy, which 









of 135 patients with LN 
metastasis at RNU for UTUC
 


















Tumour necrosis 75 (55.6)
Concomitant CIS 58 (43.0)
LVI 97 (71.9)
No. of LNs examined











No of LNs involved with cancer











LND, % 50 (3–100)








Univariable and multivariable Cox regression analyses predicting disease relapse and DSS in 135 






































Tumour grade (high vs low) 4.10; 0.02 2.88; 0.09
LVI 1.16; 0.13 0.97; 0.57
LND (threshold 30%) 2.61; 0.03 1.84; 0.05
Predictive accuracy, %





 LND 30% 69.8







































Tumour grade (high vs low) 4.93; 0.03 2.84; 0.16
LVI 1.23; 0.11 0.98; 0.17
LND (threshold 30%) 2.31; 0.03 1.73; 0.04
Predictive accuracy, %





 LND 30% 68.1
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We evaluated the LND concept for the first 
time in UTUC and found that LND using a 
threshold of 30% was a powerful predictor of 
disease recurrence and DSS in patients with 
LN-positive UTUC after RNU. Of patients with 




30%, 25 and 30% had cancer 
recurrence and died within 5 years of RNU, 
respectively, compared to 38% and 48% with 
a LND of ≥30%, respectively. In multivariable 
analyses that adjusted for the effects 
of standard pathological features (i.e. 
pathological stage, tumour grade and LVI), 
patients with a LND of ≥30% had 1.8 times 
the risk of disease recurrence and 1.7 times 
the risk of disease-specific death after RNU 
than patients with a LND of <30%. Moreover, 
adding LND using a threshold of 30% 
improved the predictive accuracies of the 
base models including standard pathological 
features for predicting both disease 
recurrence and DSS, by a prognostic and 
clinically significant margin.
The overall incidence of LN-positive disease at 
RNU in the present series was 31% (135 of 
432 patients) which is within the range of 
previous reports [5,6]. Nodal metastasis at 
RNU portends a poor prognosis, with survival 
rates in earlier series as low as ≈10% [7]. In 
bladder cancer, recent series show improved 
survival in patients who have positive LNs, 
with 5-year overall and RFS rates of 20–30%, 
possibly due to more complete LN dissection 
[11,22].
Recently, increasingly many reports show 
advantages for the concept of LND compared 
to or in addition to the absolute number of 
involved LNs in predicting RFS of patients 
with LN-positive cancer [14,16,17]. This 
concept incorporates the tumour burden and 
the extent of LN dissection. To our knowledge, 
the LND concept has never been evaluated in 
UTUC. In the present study we tested the 
predictive value of LND in a large multicentre 
retrospective dataset of patients with LN-
positive UTUC. LND and pathological tumour 
stage were the only features independently 
associated with disease recurrence and 
survival in patients with LN-positive UTUC. In 
addition, similar to a previous study in bladder 
UC, we found that LND was a more powerful 
predictor of RFS than the absolute numbers of 
involved LNs [14]. Only the combination of the 
number of involved LNs and the number of 
examined LNs was statistically significant for 
outcomes. This could be explained because 
the LND takes into account the potential 
therapeutic value of a locoregional LN 
dissection. This finding is of potential clinical 
significance, as LND is a variable that can, at 
least in theory, be influenced by the surgeon 
through an extended lymphadenectomy. 
Furthermore, LND remained a significant 
predictor of clinical outcomes after adjusting 
for the effect of adjuvant chemotherapy. We 
identified 30% as the best LND threshold for 
stratifying patients into significantly different 
risk groups. This threshold was established 
after systematically assessing the association 
of 10% increments of LND with clinical 
outcomes after RNU. While all patients with 
LN-positive disease have a poor prognosis, 
patients with a LND of ≥30%, regardless of 
pathological features, have significantly 
worse survival rates than those with a LND of 
<30%, and therefore might benefit from early 
aggressive therapy.
There are several limitations to the present 
study. Although we used many internal and 
external reviews of the dataset, we excluded 
from this analysis patients for whom we could 
not obtain complete information, possibly 
creating a selection bias. Additional biases 
include differences in the performance of the 
lymphadenectomy, and the extent and 
location of the lymphadenectomy, by study 
site and individual surgeon. As to the extent 
of lymphadenectomy in the present series, our 
model of LND is based on relatively few LNs 
removed during RNU. Thus, the reliability 
of a threshold of 30% can be questioned. 
Furthermore, for the number of evaluated 
LNs, there is a discrepancy between the group 
of patients with a LND of <30% (median 10 
LNs) and those with a LND of >30% (median 
two LNs). This might reflect a bias, but 
patients with a LND of <30% have obviously 
had a more extended lymphadenectomy, 
which contributed to a lower LND value and 
translated into a better outcome in the 
present study. However, that neither the total 
number of LNs examined nor the total 
number of LNs involved with cancer were 
associated with disease recurrence or DSS 
suggests that the extent of lymphadenectomy 
was insufficient in most patients.
Finally, review and interpretation by many 
genitourinary pathologists can potentially 
introduce a diagnostic bias. While these biases 
cannot be controlled for in the analysis, the 
multi-institutional nature of our study and 
the use of ‘local’ pathological interpretation 
might make our conclusions more relevant 
and applicable in both the academic and 
community settings, reflecting a more 
realistic picture of the management of UTUC.
Nonetheless, even with these limitations and 
being aware of the fact that LND as a ratio 
must be interpreted with caution, our results 
suggest that the concept of LND is relevant in 
patients with UTUC who are treated with 
RNU, even after adjusting for adjuvant 
chemotherapy.
We conclude that LND is an independent 
predictor of clinical outcomes in patients 
with UTUC treated with RNU. Our findings 
also support recent evidence that 
lymphadenectomy performed in conjunction 
with RNU has a therapeutic role in LN-
FIG. 1. Kaplan-Meier estimates for RFS (A) and DSS 
(B) in 135 LN-positive patients after RNU when 
stratified by a LND threshold of 30%. Patients with a 
LND of <30% (blue curve; 39) were at significantly 
lower risk of disease recurrence and disease-specific 
death than patients with a LND of ≥30% (green 
curve; 96) (P = 0.021 and 0.032, respectively). The 
boxes include the number of patients still at risk 
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positive patients with UTUC. Thus we 
furthermore argue in favour of extended 
lymphadenectomy in these patients, as it 
decreases the LND ratio. LND offers an 
attractive proxy measure of quality of care 
and might be useful in future staging systems. 
Moreover, future adjuvant therapies and 
clinical trials should consider applying the 
LND concept, as it might help to reduce the 
surgical bias and the bias in the extent of 
lymphadenectomy, both of which are 
currently not standardized. Our preliminary 
data support systematic nodal ratio analysis 
from multi-institutional patient datasets. 
A prospective validation of LND and 
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